NanoViricides Statistics
Total Valuation
NanoViricides has a market cap or net worth of $34.17 million. The enterprise value is $30.05 million.
| Market Cap | 34.17M |
| Enterprise Value | 30.05M |
Important Dates
The last earnings date was Friday, May 15, 2026, before market open.
| Earnings Date | May 15, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NanoViricides has 22.78 million shares outstanding. The number of shares has increased by 32.11% in one year.
| Current Share Class | 22.78M |
| Shares Outstanding | 22.78M |
| Shares Change (YoY) | +32.11% |
| Shares Change (QoQ) | +8.86% |
| Owned by Insiders (%) | 0.56% |
| Owned by Institutions (%) | 8.34% |
| Float | 22.18M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.15 |
| P/TBV Ratio | 3.76 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.17
| Current Ratio | 3.17 |
| Quick Ratio | 3.02 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -89.97% and return on invested capital (ROIC) is -56.82%.
| Return on Equity (ROE) | -89.97% |
| Return on Assets (ROA) | -50.46% |
| Return on Invested Capital (ROIC) | -56.82% |
| Return on Capital Employed (ROCE) | -89.32% |
| Weighted Average Cost of Capital (WACC) | 13.43% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.16M |
| Employee Count | 7 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +8.70% in the last 52 weeks. The beta is 1.67, so NanoViricides's price volatility has been higher than the market average.
| Beta (5Y) | 1.67 |
| 52-Week Price Change | +8.70% |
| 50-Day Moving Average | 1.45 |
| 200-Day Moving Average | 1.29 |
| Relative Strength Index (RSI) | 55.89 |
| Average Volume (20 Days) | 355,649 |
Short Selling Information
The latest short interest is 754,181, so 3.31% of the outstanding shares have been sold short.
| Short Interest | 754,181 |
| Short Previous Month | 702,023 |
| Short % of Shares Out | 3.31% |
| Short % of Float | 3.40% |
| Short Ratio (days to cover) | 0.37 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -8.18M |
| Pretax Income | -8.09M |
| Net Income | -8.09M |
| EBITDA | -7.62M |
| EBIT | -8.18M |
| Earnings Per Share (EPS) | -$0.43 |
Balance Sheet
The company has $3.21 million in cash and n/a in debt, with a net cash position of $3.21 million or $0.14 per share.
| Cash & Cash Equivalents | 3.21M |
| Total Debt | n/a |
| Net Cash | 3.21M |
| Net Cash Per Share | $0.14 |
| Equity (Book Value) | 9.15M |
| Book Value Per Share | 0.42 |
| Working Capital | 2.31M |
Cash Flow
In the last 12 months, operating cash flow was -$7.28 million and capital expenditures -$94,516, giving a free cash flow of -$7.37 million.
| Operating Cash Flow | -7.28M |
| Capital Expenditures | -94,516 |
| Depreciation & Amortization | 556,663 |
| Net Borrowing | n/a |
| Free Cash Flow | -7.37M |
| FCF Per Share | -$0.32 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NanoViricides does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -32.11% |
| Shareholder Yield | -32.11% |
| Earnings Yield | -24.33% |
| FCF Yield | -22.16% |
Analyst Forecast
The average price target for NanoViricides is $6.00, which is 300.00% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $6.00 |
| Price Target Difference | 300.00% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 24, 2019. It was a reverse split with a ratio of 1:20.
| Last Split Date | Sep 24, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |